Vanderbilt University

Boehringer Ingelheim International Gmbh

Kenneth M Meyers

Shaun R Stauffer

Taekyu Lee

Stephen W Fesik

Derek Cogan

Keith R Hornberger

Zhonghua Zhang

Zhaoming Xiong

Rocco D Gogliotti

Jonathan D Macdonald

Jianhua Tian

James M Salovich

Maolin Yu

John Lord

Xin Guo

Michael Balestra

Changho Han

Jennifer Burke

Joseph R Alvarado

Jonathan J Mills

KyuOk Jeon

Somenath Chowdhury

Jörg Bentzien

Kevin B Teuscher

Isoquinolinone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

WDR5 inhibitors and modulators

Described are imino-azacycle-benzamide compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.

Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.

WDR5-MLL1 inhibitors and modulators

Growing community of inventors

Nashville, TN, United States of America

Kenneth M Meyers